Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...
From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting candidates allowing once-monthly administration may become the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback